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Nutritional and respiratory care are the most important 
symptomatic and supportive treatments for patients 
with amyotrophic lateral sclerosis (ALS). Non-invasive 
ventilation prolongs survival and maintains overall 
quality of life, and is now regarded as the standard of 
care for patients whose forced vital capacity is reduced 
to 50% or less.1,2 However, this technique is not without 
its shortcomings: some patients simply cannot tolerate 
it and others have asynchronisation with their own 
breathing, causing poor sleep.3 Ultimately, non-invasive 
ventilation may not be able to support patients’ 
progressive hypoventilation fully, prompting the need 
for decision making regarding tracheostomy with 
invasive ventilation or palliative care.1,2
 The NeuRx 4/4 Diaphragm Pacing System has been 
developed as an assistive medical device to improve 
respiratory failure caused by diaphragmatic weakness, 
mainly in patients with spinal-cord injuries.4 Four 
stimulators on the lower diaphragmatic surface are 
endoscopically placed at or near the neuromuscular 
junction where the best contractile responses are 
observed. A multicentre study5 was done in patients 
with ALS, showing prolongation of survival in patients 
treated with the Diaphragm Pacing System compared 
with published historical data for non-invasive 
ventilation as the control. On the basis of these results, 
in 2011, the device received Humanitarian Device 
Exemption approval from the US Food and Drug 
Administration (FDA).6 At that time, a cautionary 
commentary urged for a scientiﬁ c publication of 
that study and further randomised controlled trials.7 
Retrospectively, that no data from the original study 
were published in scientiﬁ c papers that had undergone 
vigorous peer review was an early warning sign.
To my knowledge, only three randomised controlled 
studies investigating diaphragm pacing in ALS have 
been independently initiated, and one of the studies is 
published in The Lancet Neurology.8 In this study, done by 
the DiPALS Study Group collaborators, the combination 
of non-invasive ventilation and diaphragm pacing was 
worse than non-invasive ventilation alone for survival 
(median 11·0 months vs 22·5 months; adjusted hazard 
ratio 2·27, 95% CI 1·22–4·25; p=0·009). The investigators 
would not recommend the use of diaphragm pacing 
in patients with ALS who develop hypoventilation. 
The other two studies investigating application of 
diaphragm pacing are still pending (ClinicalTrials.gov, 
numbers NCT01938495 and NCT01583088).
This report8 certainly triggers several important and 
intriguing questions. Why are the results from this study 
so diﬀ erent from those of the earlier study, which led to 
FDA humanitarian exemption? Whereas drug approval 
from the FDA usually requires two pivotal randomised 
trials to be done, approval for a medical device does 
not. Although it is our responsibility to bring either 
pharmacological or non-pharmacological treatment 
to patients with this devastating disease at the earliest 
opportunity, we also have a strong obligation to protect 
patients from uncertain treatment. 
Because the makers of the pacing system and key 
investigators involved in the study that led to the 
humanitarian device exemption5 have the scientiﬁ c 
expertise and necessary resources, a randomised 
controlled trial should have expeditiously followed 
the initial promising results. Once a drug or device is 
approved by the FDA, a formal investigation examining 
eﬃ  cacy becomes much harder to undertake, which 
might have contributed to the slow recruitment in 
the US diaphragm pacing study (NCT01938495; 
Katz J, California Paciﬁ c Medical Center, CA, USA, 
personal communication). Another important question 
is how useful and reliable the historical controls are 
when compared with the results of the previous 
diaphragm pacing study.5 Historical controls were Dr P
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Constraint-induced movement therapy translated into 
practice
Constraint-induced movement therapy (CIMT) is 
the massed task practice of the aﬀ ected limb with 
shaping techniques and constraint of the unaﬀ ected 
limb. CIMT and modiﬁ ed CIMT are the most 
empirically supported approaches to rehabilitation 
of the upper limbs after stroke. CIMT is a successful 
example1 of translating ﬁ ndings from basic research 
(from animal studies),2 to human clinical research 
(including phase 1–3 clinical trials)3,4 and practice-
based research (phase 3 randomised trials).5–7 In one 
study5 of 222 patients with stroke-related upper limb 
dysfunction, the eﬀ ect of CIMT given before or after 
routine therapy was compared with standard care; 
however, without data from clinical practice, the 
assessment of CIMT or modiﬁ ed CIMT is arguably a 
conceptual investigation that will not beneﬁ t patients 
who receive regular therapy at clinics. In The Lancet 
Neurology, Anne Barzel and colleagues7 now report 
used for the ﬁ rst time in ALS in a study investigating 
lithium carbonate,9 in response to a report describing 
the potential beneﬁ ts with lithium that triggered 
a frenzy of hope in the ALS community. The use of 
historical controls was well justiﬁ ed in the case of 
lithium because various randomised controlled trials 
with lithium were already on the horizon. Yet nearly 
everyone agrees that studies with historical controls 
are useful only for probing of possibilities, and that 
any possible eﬃ  cacy shown should be followed by 
appropriate randomised controlled trials. Because 
the ALS community has already accumulated a large 
amount of data, meaningful historical control-based 
studies might become a viable option in the future,10 
but how to select historical controls in each trial is still 
an issue of fundamental importance. 
Although the DiPALS investigators fully discuss 
possible reasons for poor outcomes with non-invasive 
ventilation and diaphragm pacing in their report,8 the 
mechanisms of why this happened could have been 
investigated with use of periodical nocturnal pulse 
oximetry and, in selected patients, polysomnograms 
could have been obtained. This information would have 
helped us learn how to manage non-invasive ventilation 
in the future. Our experience with diaphragm pacing 
raises several important questions of how to undertake 
ALS clinical trials properly and from early stages. There 
is a strong need for new international guidelines 
for clinical trials of ALS, which would detail how to 
undertake more eﬀ ective and eﬃ  cient clinical trials in 
the future, especially because the current guidelines are 
already 16 years old.11 
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